% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Doppler:163310,
author = {Doppler, Christopher E J and Kinnerup, Martin B and Brune,
Corinna and Farrher, Ezequiel and Betts, Matthew and
Fedorova, Tatyana D and Schaldemose, Jeppe L and Knudsen,
Karoline and Ismail, Rola and Seger, Aline D and Hansen,
Allan K and Stær, Kristian and Fink, Gereon R and Brooks,
David J and Nahimi, Adjmal and Borghammer, Per and
Sommerauer, Michael},
title = {{R}egional locus coeruleus degeneration is uncoupled from
noradrenergic terminal loss in {P}arkinson's disease.},
journal = {Brain},
volume = {144},
number = {9},
issn = {1460-2156},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DZNE-2022-00090},
pages = {2732 - 2744},
year = {2021},
abstract = {Previous studies have reported substantial involvement of
the noradrenergic system in Parkinson's disease.
Neuromelanin-sensitive MRI sequences and PET tracers have
become available to visualize the cell bodies in the locus
coeruleus and the density of noradrenergic terminal
transporters. Combining these methods, we investigated the
relationship of neurodegeneration in these distinct
compartments in Parkinson's disease. We examined 93 subjects
(40 healthy controls and 53 Parkinson's disease patients)
with neuromelanin-sensitive turbo spin-echo MRI and
calculated locus coeruleus-to-pons signal contrasts. Voxels
with the highest intensities were extracted from published
locus coeruleus coordinates transformed to individual MRI.
To also investigate a potential spatial pattern of locus
coeruleus degeneration, we extracted the highest signal
intensities from the rostral, middle, and caudal third of
the locus coeruleus. Additionally, a study-specific
probabilistic map of the locus coeruleus was created and
used to extract mean MRI contrast from the entire locus
coeruleus and each rostro-caudal subdivision. Locus
coeruleus volumes were measured using manual segmentations.
A subset of 73 subjects had 11C-MeNER PET to determine
noradrenaline transporter density, and distribution volume
ratios of noradrenaline transporter-rich regions were
computed. Patients with Parkinson's disease showed reduced
locus coeruleus MRI contrast independently of the selected
method (voxel approaches: P < 0.0001, P < 0.001;
probabilistic map: P < 0.05), specifically on the
clinically-defined most affected side (P < 0.05), and
reduced locus coeruleus volume (P < 0.0001). Reduced MRI
contrast was confined to the middle and caudal locus
coeruleus (voxel approach, rostral: P = 0.48, middle: P <
0.0001, and caudal: P < 0.05; probabilistic map, rostral: P
= 0.90, middle: P < 0.01, and caudal: P < 0.05). The
noradrenaline transporter density was lower in patients with
Parkinson's diseasein all examined regions (group effect P <
0.0001). No significant correlation was observed between
locus coeruleus MRI contrast and noradrenaline transporter
density. In contrast, the individual ratios of noradrenaline
transporter density and locus coeruleus MRI contrast were
lower in Parkinson's disease patients in all examined
regions (group effect P < 0.001). Our multimodal imaging
approach revealed pronounced noradrenergic terminal loss
relative to cellular locus coeruleus degeneration in
Parkinson's disease; the latter followed a distinct spatial
pattern with the middle-caudal portion being more affected
than the rostral part. The data shed first light on the
interaction between the axonal and cell body compartments
and their differential susceptibility to neurodegeneration
in Parkinson's disease, which may eventually direct research
towards potential novel treatment approaches.},
keywords = {Aged / Aged, 80 and over / Female / Humans / Locus
Coeruleus: diagnostic imaging / Locus Coeruleus: metabolism
/ Magnetic Resonance Imaging: methods / Male / Middle Aged /
Multimodal Imaging: methods / Norepinephrine Plasma Membrane
Transport Proteins: metabolism / Parkinson Disease:
diagnostic imaging / Parkinson Disease: metabolism /
Positron-Emission Tomography: methods / MeNER (Other) /
Parkinson’s disease (Other) / neuromelanin (Other) /
noradrenaline (Other) / positron emission tomography (Other)
/ Norepinephrine Plasma Membrane Transport Proteins (NLM
Chemicals) / SLC6A2 protein, human (NLM Chemicals)},
cin = {AG Düzel},
ddc = {610},
cid = {I:(DE-2719)5000006},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34196700},
doi = {10.1093/brain/awab236},
url = {https://pub.dzne.de/record/163310},
}